Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis
ConclusionsCertain DMTs have the potential to positively impact QoL of PwMS, and the assessment and reporting of QoL is suboptimal with a multitude of diverse instruments being used. There is an urgent need that design and reporting of clinical trials reflect the critical importance of QoL for PwMS. (Source: Journal of Neurology)
Source: Journal of Neurology - April 16, 2024 Category: Neurology Source Type: research
Real-world evidence and patient preference for subcutaneous < em > versus < /em > intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study
CONCLUSION: Based on current data, there is a trend toward patients' preference for the natalizumab SC route over the IV route, which provides valuable insights into patients' preference for natalizumab RoA in routine care and complements available data from clinical studies with real-world data on SC natalizumab.TRIAL REGISTRATION: This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).PMID:38616781 | PMC:PMC11015759 | DOI:10.1177/17562864241241382 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Ralf Gold Stephan Schmidt Florian Deisenhammer Jeremias Motte Nils Richter Kirsi Taipale Hans Christian Salmen Christian Bohland Ksenija Schirduan Source Type: research
Real-world evidence and patient preference for subcutaneous < em > versus < /em > intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study
CONCLUSION: Based on current data, there is a trend toward patients' preference for the natalizumab SC route over the IV route, which provides valuable insights into patients' preference for natalizumab RoA in routine care and complements available data from clinical studies with real-world data on SC natalizumab.TRIAL REGISTRATION: This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).PMID:38616781 | PMC:PMC11015759 | DOI:10.1177/17562864241241382 (Source: Adv Data)
Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Ralf Gold Stephan Schmidt Florian Deisenhammer Jeremias Motte Nils Richter Kirsi Taipale Hans Christian Salmen Christian Bohland Ksenija Schirduan Source Type: research
Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center
ConclusionATZ is a high efficacy therapy for active MS, providing long-term remission in a significant proportion of patients. Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs. (Source: Acta Neurologica Belgica)
Source: Acta Neurologica Belgica - April 15, 2024 Category: Neurology Source Type: research
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Natalizumab treatment in relapsing-remitting multiple sclerosis: can we safely personalise treatment intervals? In JNNP, Toorop and coworkers present the results of the NEXT-MS trial, a clinical trial on individualised extended interval dosing (EID) of natalizumab (NTZ) in people with relapsing-remitting multiple sclerosis (RRMS).1 NTZ was one of the first high-efficacy treatments in RRMS, and has remained popular since its introduction in the late 2000s. NTZ is typically administered at a dose of 300 mg every 4 weeks. The two pivotal phase 3 NTZ trials, AFFIRM2 and SENTINEL3 were published back-to-back in the New England ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 12, 2024 Category: Neurosurgery Authors: Koch, M. Tags: Editorial commentaries Source Type: research
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Conclusions
MS disease activity is adequately controlled with personalised natalizumab EID. Interval extension to a drug trough concentration of 5 µg/mL is likely a safe target to extend natalizumab treatment intervals >6 weeks.
Trial registration number
NCT04225312. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - April 12, 2024 Category: Neurosurgery Authors: Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurel Tags: Editor's choice Multiple sclerosis Source Type: research
Iraqi experts consensus on the management of relapsing remitting multiple sclerosis in adults
This study aimed to develop consensus recommendations regarding the diagnosis and management of MS in Iraq, specifically focusing on treatment-naïve patients, suboptimal responders, and women of childbearing age during preconception, pregnancy planning, and lactation. A survey was conducted to collect feedback from a panel of ten key opinion leaders (KOLs), who evaluated and discussed the statements to determine agreement levels. The mini-Delphi method was employed to establish a consensus on the management recommendations, and a meeting was held to analyze the responses and ensure that the recommendations were based on c...
Source: Current Medical Research and Opinion - April 11, 2024 Category: Research Authors: Hayder K Hassoun Anmar Oday Hatem Akram Al-Mahdawi Sarwer Jamal Al-Bajalan Ali Kadim Karim Sarmad Abdulrasool Al-Mashta Saif Mohammed Tawfeeq Majeed Salih Hamad Nawfal M Sheaheed Samer Mohammed Ridha Murad Al-Naqshbandi Hasan Aziz Al-Hamadani Source Type: research
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design
DISCUSSION: The CLADRINA trial will generate data regarding the safety, efficacy, and immunological impact of the transition from natalizumab to cladribine. As the pace of immunological knowledge of MS continues, insight into disease modifying therapy transition strategies is needed.PMID:38585373 | PMC:PMC10996356 | DOI:10.1177/17562864241233858 (Source: Adv Data)
Source: Adv Data - April 8, 2024 Category: Epidemiology Authors: Peter V Sguigna Rehana Z Hussain Annette Okai Kyle M Blackburn Lauren Tardo Mariam Madinawala Julie Korich Lori A Lebson Jeffrey Kaplan Amber Salter Navid Manouchehri Olaf Stuve Source Type: research
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design
DISCUSSION: The CLADRINA trial will generate data regarding the safety, efficacy, and immunological impact of the transition from natalizumab to cladribine. As the pace of immunological knowledge of MS continues, insight into disease modifying therapy transition strategies is needed.PMID:38585373 | PMC:PMC10996356 | DOI:10.1177/17562864241233858 (Source: Adv Data)
Source: Adv Data - April 8, 2024 Category: Epidemiology Authors: Peter V Sguigna Rehana Z Hussain Annette Okai Kyle M Blackburn Lauren Tardo Mariam Madinawala Julie Korich Lori A Lebson Jeffrey Kaplan Amber Salter Navid Manouchehri Olaf Stuve Source Type: research
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review
ConclusionAvailable information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - April 7, 2024 Category: Drugs & Pharmacology Source Type: research
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry
CONCLUSION: The initial use of MME DMTs was among the strongest predictors of DMT discontinuation in a large German retrospective MS cohort, arguing for the need for prospective treatment strategy trials, not only but also on the initial broad use of HE DMTs in PwMS.PMID:38560408 | PMC:PMC10981260 | DOI:10.1177/17562864241239740 (Source: Adv Data)
Source: Adv Data - April 1, 2024 Category: Epidemiology Authors: Niklas Frahm David Ellenberger Alexander Stahmann Firas Fneish Daniel L üftenegger Hans C Salmen Ksenija Schirduan Tom P A Schaak Peter Flachenecker Christoph Kleinschnitz Friedemann Paul Dagmar Krefting Uwe K Zettl Melanie Peters Clemens Warnke Source Type: research
